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Introduction {#sec001}
============

Influenza B is a member of the *Orthomyxoviridae* family and has an enveloped structure and segmented negative sense RNA genome \[[@pone.0170610.ref001]\], and is an important cause of respiratory infections in humans globally. The genome organization of influenza B virus is similar to that of influenza A virus, which consists of eight segments: polymerase basic-1 (PB1), polymerase basic-2 (PB2), polymerase acidic (PA), hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), matrix protein (MP), and non-structural protein (NS) \[[@pone.0170610.ref001]\]. First isolated in 1940 during an epidemic in the USA \[[@pone.0170610.ref002]\], influenza B viruses have been detected in different geographical regions worldwide \[[@pone.0170610.ref003]\]. In the 1980s, two antigenically and genetically distinct lineages, B/Victoria/2/1987-like (Victoria lineage) and B/Yamagata/16/88-like (Yamagata lineage), have co-circulated in the human population, based on analysis of the HA gene \[[@pone.0170610.ref004]\].

Segment reassortment between Victoria and Yamagata lineages based on phylogenetic analysis of the HA and NA genes has been reported since 1999 \[[@pone.0170610.ref005]\] as a result of unrestricted lineage mixing \[[@pone.0170610.ref006]\]. An extensive analysis of the whole genome of influenza B viruses in previous studies showed that frequent and complex reassortment of all eight gene segments between and within Victoria and Yamagata lineages continues to play a role in determining the evolutionary changes in both lineages \[[@pone.0170610.ref007]--[@pone.0170610.ref009]\]. As evident in our recent cross-sectional molecular epidemiological study of influenza B virus, conducted among patients who presented with acute upper respiratory tract infections (URTI) between 2012 and 2014 in Kuala Lumpur, Malaysia \[[@pone.0170610.ref010]\], it was suggested that the emergence of B/Phuket/3073/2013-like viruses circulating in this country and globally was due to an intra-clade reassortment event within Yamagata Clade 3 (Yam-3), one of the WHO genetic groups within Yamagata lineage \[[@pone.0170610.ref011], [@pone.0170610.ref012]\]. This resulted in the selection of B/Phuket/3073/2013-like virus as a candidate vaccine strain by the WHO for both northern and southern hemispheres for the 2015--2016 influenza season \[[@pone.0170610.ref011], [@pone.0170610.ref012]\].

Previously, the phylogeny of HA and NA genes that we determined allows grouping of influenza B viruses into lineages, WHO genetic groupings (clades) and sub-clades \[[@pone.0170610.ref010]\], and this permits more detailed classification of inter-clade or intra-clade reassortants. However, these groupings were not extended to other gene segments of the influenza B genome. Most whole-genome studies on influenza B viruses only described reassortment patterns of gene segments between lineages (or at the lineage level) \[[@pone.0170610.ref007], [@pone.0170610.ref013]--[@pone.0170610.ref018]\] and have not described reassortment patterns at the clade and sub-clade levels. The evidence for segment reassortment within a lineage or clade in contributing to worldwide disease certainly warrants a more detailed and systematic approach of phylogenetic classification of all gene segments \[[@pone.0170610.ref010]\]. Hence, in this study, we aimed to examine the reassortment patterns at the lineage, clade and sub-clade levels by performing phylogenetic analysis on the whole genome of influenza B/Phuket/3073/2013-like viruses and unique reassortants detected in Malaysia.

Materials and Methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

This study was approved by the University of Malaya Medical Centre (UMMC) Medical Ethics Committee (MEC890.1). Standard, multilingual consent forms were used and written consent was obtained from all prospectively-recruited study participants. Written consent was also obtained from the next of kin, caretakers, or guardians on behalf of the minors/children enrolled in this study.

Sample collection and detection of influenza B viruses {#sec004}
------------------------------------------------------

A total of 3,935 nasopharyngeal swab samples were prospectively collected from children and adult outpatients at the Primary Care Clinic of UMMC in Kuala Lumpur, Malaysia between 2012 and 2014 \[[@pone.0170610.ref010]\]. All patients experienced symptoms of acute URTI. These were tested for influenza B with the xTAG Respiratory Virus Panel (RVP) FAST multiplex RT-PCR assay (Abbott Molecular, Toronto, Canada) used with the Universal Tag sorting system on a Luminex 200 IS platform (Luminex Corp., Austin, Texas, USA), according to the manufacturer's protocol \[[@pone.0170610.ref019]\]. In addition, 59 influenza B isolates from children (1 month to 15 years old) who were admitted to the hospital between January 2009 and June 2015 were also included in this study. They were obtained from the stocked cultures of the diagnostic virology laboratory of UMMC. These influenza B viruses had been cultured from nasopharyngeal aspirates in Madin-Darby canine kidney (ATCC number CCL-34) cells and confirmed by immunofluorescence assay with the Light Diagnostic Respiratory Panel 1 Viral Screening & Identification Kit (Millipore, Billerica, USA).

Whole-genome sequencing of influenza B viruses {#sec005}
----------------------------------------------

Using viral RNA extracted by NucliSENS easyMAG automated nucleic acid extraction system (bioMérieux, Marcy I'Etoile, France) \[[@pone.0170610.ref020]\] as template, all gene segments (PB2, PB1, PA, HA, NP, NA, MP and NS) of selected samples with unique HA-NA reassortment properties were amplified by two-step reverse transcription polymerase chain reaction (RT-PCR) using reagents and cycling conditions \[[@pone.0170610.ref021]\] listed in [S1 Table](#pone.0170610.s004){ref-type="supplementary-material"}. Sequences of universal primer and primer sets for all eight gene segments are listed in [S2 Table](#pone.0170610.s005){ref-type="supplementary-material"}. Sequencing of PCR products was performed in an ABI PRISM 3730XL Genetic Analyzer using the BigDye Terminator v3.1 cycle sequencing kit chemistry (Applied Biosystems, California, USA). Lastly, sequence reads were assembled into a contig and manually edited using BioEdit 7.2 to produce a final sequence of full-length protein-coding region of each gene segment. All sequences generated in this study are available in GenBank under accession numbers KX269900-KX270009.

Phylogenetic analysis {#sec006}
---------------------

In order to investigate the reassortment pattern among the selected Malaysian influenza B reassortants, phylogenetic analysis was conducted on all eight gene segments. All Malaysian sequences were first aligned with WHO recommended candidate vaccine and reference sequences, as well as selected strains from other countries retrieved from the NCBI Influenza Virus Resource \[[@pone.0170610.ref022]\] and the Global Initiative on Sharing all Influenza Data (GISAID) database \[[@pone.0170610.ref023]\] (accessed on January 14, 2016) ([Table 1](#pone.0170610.t001){ref-type="table"}) using a web-based multiple sequence alignment program MAFFT \[[@pone.0170610.ref024]\]. Phylogenetic tree reconstructions of all genes were performed using maximum likelihood (ML) method heuristically inferred using subtree pruning and regrafting and nearest neighbor interchange algorithms with general time-reversible (GTR) nucleotide substitution model, a proportion of invariant sites (+I) and four categories of gamma rate heterogeneity (+Γ~4~), implemented in PAUP version 4.0 \[[@pone.0170610.ref025]\]. Robustness of the branching orders was evaluated by bootstrap analysis.

10.1371/journal.pone.0170610.t001

###### Accession numbers of influenza B sequences in NCBI Influenza Virus Resource and GISAID used for the phylogenetic reconstruction of PB1, PB2, PA, HA, NP, NA, MP and NS genes.

![](pone.0170610.t001){#pone.0170610.t001g}

  Properties      Strains                      Collection Date/Year   Accession Number for gene:                                                                                                                                                                                                                                              
  --------------- ---------------------------- ---------------------- ----------------------------------------------- ----------------------------------------------- ----------------------------------------------- ----------- ----------------------------------------------- ----------- ----------------------------------------------- -----------------------------------------------
  Reference       B/Lee/40                     1940                   DQ792895                                        DQ792894                                        DQ792896                                        DQ792897    DQ792898                                        DQ792899    DQ792900                                        DQ792901
  Reference       B/Yamagata/16/88             1988                   CY018771                                        CY018772                                        CY018770                                        CY018765    CY018768                                        CY018767    CY018766                                        CY018769
  Reference       B/Victoria/02/1987           1987                   CY018763                                        CY018764                                        CY018762                                        CY018757    CY018760                                        CY018759    CY018758                                        CY018761
  WHO Vaccine     B/Brisbane/3/2007            2007-03-09             CY155904                                        CY155905                                        CY155903                                        CY155898    CY155901                                        CY155900    CY155899                                        CY155902
  WHO Vaccine     B/Florida/4/2006             2006                   CY033882                                        CY033883                                        CY033881                                        CY073895    CY033879                                        CY033878    CY033877                                        CY033880
  WHO Vaccine     B/Massachusetts/02/2012      2012-03-13             EPI439263                                       EPI439262                                       EPI439261                                       EPI376346   EPI439258                                       EPI376345   EPI439260                                       EPI439259
  WHO Vaccine     B/Phuket/3073/2013           2013-11-21             EPI544262                                       EPI544261                                       EPI547694                                       EPI544264   EPI544260                                       EPI544263   EPI592901                                       EPI547693
  WHO Vaccine     B/Brisbane/09/2014           2014-03-24             EPI544257                                       EPI544256                                       EPI544255                                       EPI544259   EPI544253                                       EPI544258   EPI544397                                       EPI544254
  WHO Vaccine     B/Utah/09/2014               2014-05-29             EPI544271                                       EPI544270                                       EPI544269                                       EPI544273   EPI544268                                       EPI544272   EPI544396                                       EPI544395
  WHO Vaccine     B/Wisconsin/01/2010          2010-02-20             CY115189                                        CY115190                                        CY115188                                        CY115183    CY115186                                        CY115185    CY115184                                        CY115187
  WHO Vaccine     B/Hubei-Wujiagang/158/2009   2009                   CY115389                                        CY115390                                        CY115388                                        CY115383    CY115386                                        CY115385    CY115384                                        CY115387
  WHO Vaccine     B/Texas/06/2011              2011-02-16             EPI354063                                       EPI331184                                       EPI331183                                       EPI331186   EPI354062                                       EPI331185   EPI331182                                       EPI331181
  WHO Reference   B/Stockholm/12/2011          2011-02-28             \-                                              \-                                              \-                                              EPI357403   \-                                              EPI357402   \-                                              EPI357401
  WHO Vaccine     B/Bangladesh/3333/2007       2007                   CY115261                                        CY115262                                        CY115260                                        CY115255    CY115258                                        CY115257    CY115256                                        CY115259
  WHO Vaccine     B/Brisbane/33/2008           2008-07-13             EPI370452                                       EPI370453                                       EPI370451                                       EPI163726   EPI370450                                       EPI186302   EPI370449                                       EPI370448
  WHO Vaccine     B/Brisbane/60/2008           2008-08-04             CY115157                                        CY115158                                        CY115156                                        CY115151    CY115154                                        CY115153    CY115152                                        CY115155
  WHO Vaccine     B/Nevada/03/2011             2011-02-02             EPI354045                                       EPI354044                                       EPI354043                                       EPI331151   EPI354041                                       EPI331150   EPI354042                                       EPI331149
  WHO Vaccine     B/Texas/02/2013              2013-01-09             EPI443688                                       EPI443687                                       EPI443686                                       EPI443690   EPI447191                                       EPI443689   EPI447193                                       EPI447192
  WHO Vaccine     B/Bangladesh/5945/2009       2009-09-30             CY115365                                        CY115366                                        CY115364                                        CY115359    CY115362                                        CY115361    CY115360                                        CY115363
  WHO Vaccine     B/Hong Kong/259/2010         2010                   CY115197                                        CY115198                                        CY115196                                        CY115191    CY115194                                        CY115193    CY115192                                        CY115195
  WHO Reference   B/Hong Kong/514/2009         2009-10-11             \-                                              \-                                              \-                                              EPI243627   \-                                              EPI243626   \-                                              \-
  Reference       B/Bahrain/18/2013            2013-01-14             EPI491090                                       EPI491089                                       EPI491088                                       EPI491092   EPI491085                                       EPI491091   EPI491087                                       EPI491086
  Reference       B/Thailand/CU-B6096/2012     2012-03-13             JX513099                                        JX513100                                        JX513101                                        JX513102    JX513103                                        JX513104    JX513105                                        JX513106
  Reference       B/Thailand/CU-B6240/2012     2012-05-23             EPI635425                                       EPI635441                                       EPI635409                                       EPI635313   EPI635377                                       EPI635355   EPI635336                                       EPI635393
  Reference       B/Nicaragua/AGB2-26/2012     2012-08-20             EPI529042                                       EPI528983                                       EPI529041                                       EPI529036   EPI529039                                       EPI529038   EPI529037                                       EPI529040
  Reference       B/New York/1331/2012         2012-02-28             CY176007                                        CY176008                                        CY176006                                        CY176001    CY176004                                        CY176003    CY176002                                        CY176005
  Malaysian       B/Malaysia/U1429/2012        2012-11-09             KX269974[\*](#t001fn002){ref-type="table-fn"}   KX269980[\*](#t001fn002){ref-type="table-fn"}   KX269986[\*](#t001fn002){ref-type="table-fn"}   KR073380    KX269992[\*](#t001fn002){ref-type="table-fn"}   KR073549    KX269998[\*](#t001fn002){ref-type="table-fn"}   KX270004[\*](#t001fn002){ref-type="table-fn"}
  Malaysian       B/Malaysia/U2214/2013        2013-03-29             KX269975[\*](#t001fn002){ref-type="table-fn"}   KX269981[\*](#t001fn002){ref-type="table-fn"}   KX269987[\*](#t001fn002){ref-type="table-fn"}   KR073421    KX269993[\*](#t001fn002){ref-type="table-fn"}   KR073590    KX269999[\*](#t001fn002){ref-type="table-fn"}   KX270005[\*](#t001fn002){ref-type="table-fn"}
  Malaysian       B/Malaysia/U2462/2013        2013-05-31             KX269976[\*](#t001fn002){ref-type="table-fn"}   KX269982[\*](#t001fn002){ref-type="table-fn"}   KX269988[\*](#t001fn002){ref-type="table-fn"}   KR073441    KX269994[\*](#t001fn002){ref-type="table-fn"}   KR073609    KX270000[\*](#t001fn002){ref-type="table-fn"}   KX270006[\*](#t001fn002){ref-type="table-fn"}
  Malaysian       B/Malaysia/U2555/2013        2013-06-26             KX269977[\*](#t001fn002){ref-type="table-fn"}   KX269983[\*](#t001fn002){ref-type="table-fn"}   KX269989[\*](#t001fn002){ref-type="table-fn"}   KR073446    KX269995[\*](#t001fn002){ref-type="table-fn"}   KR073614    KX270001[\*](#t001fn002){ref-type="table-fn"}   KX270007[\*](#t001fn002){ref-type="table-fn"}
  Malaysian       B/Malaysia/U3224/2013        2013-12-13             KX269978[\*](#t001fn002){ref-type="table-fn"}   KX269984[\*](#t001fn002){ref-type="table-fn"}   KX269990[\*](#t001fn002){ref-type="table-fn"}   KR073450    KX269996[\*](#t001fn002){ref-type="table-fn"}   KR073617    KX270002[\*](#t001fn002){ref-type="table-fn"}   KX270008[\*](#t001fn002){ref-type="table-fn"}
  Malaysian       B/Malaysia/U3901/2014        2014-05-16             KX269979[\*](#t001fn002){ref-type="table-fn"}   KX269985[\*](#t001fn002){ref-type="table-fn"}   KX269991[\*](#t001fn002){ref-type="table-fn"}   KR073493    KX269997[\*](#t001fn002){ref-type="table-fn"}   KR073659    KX270003[\*](#t001fn002){ref-type="table-fn"}   KX270009[\*](#t001fn002){ref-type="table-fn"}

'-': Sequences not available;

'\*': Sequences that were obtained in this study.

Results and Discussion {#sec007}
======================

There were 164/3,935 (children and adult outpatients) and 37/59 (hospitalized children) nasopharyngeal samples positive for HA and NA genes of influenza B viruses ([S3 Table](#pone.0170610.s006){ref-type="supplementary-material"}). Phylogenetic analysis of both genes identified similar circulation of Yamagata- and Victoria-lineage as well as Yam-2, Yam-3 and Vic-1 viruses between children and adult outpatients, and hospitalized children ([S1](#pone.0170610.s001){ref-type="supplementary-material"} and [S2](#pone.0170610.s002){ref-type="supplementary-material"} Figs, [S3 Table](#pone.0170610.s006){ref-type="supplementary-material"}). Furthermore, the analysis showed 36 B/Phuket/3073/2013-like viruses (28 in children and adult outpatients, 8 in hospitalized children) with intra-clade reassortment properties (HA-B/Wisconsin/01/2010-like/NA-B/Stockholm/12/2012-like) within Yam-3, one unique inter-clade reassortant (HA-Yam-2/NA-Yam-3) and one unique intra-clade reassortant within Vic-1 (HA-Vic-1B/NA-Vic-1A) ([S1](#pone.0170610.s001){ref-type="supplementary-material"} and [S2](#pone.0170610.s002){ref-type="supplementary-material"} Figs, [S3 Table](#pone.0170610.s006){ref-type="supplementary-material"}). To investigate the reassortment pattern of all eight gene segments of these reassortants from the lineage to the sub-clade level, four earliest detected B/Phuket/3073/2013-like intra-clade reassortants and the two unique reassortants sampled between 2012 and 2014 were chosen for further whole-genome analysis.

The phylogenetic trees reconstructed by the ML method for PB1, PB2, PA, HA, NP, NA, MP and NS genes are illustrated in [Fig 1](#pone.0170610.g001){ref-type="fig"} and [S3 Fig](#pone.0170610.s003){ref-type="supplementary-material"}, which consist of selected Malaysian reassortants, WHO candidate vaccine and reference strains, as well as selected strains from other countries that were closely related to the selected Malaysian reassortants (≥99% sequence identities on all genes based on NCBI BLAST \[[@pone.0170610.ref026]\]). Consistent with other reports \[[@pone.0170610.ref007], [@pone.0170610.ref013], [@pone.0170610.ref015]\], the lineages for other genes (except for NS gene) were first assigned in the same manner as the HA gene, with lineages that resembled B/Yamagata/16/88-like viruses (Yam-like) designated as Lineage II, the lineages that resembled B/Victoria/2/87-like viruses (Vic-like) designated as Lineage III. The lineage that did not resemble any of the Vic- or Yam-like viruses was designated as Lineage IV (as for the case of NS gene) ([Fig 1](#pone.0170610.g001){ref-type="fig"}). Under such assignment, it was apparent that the tree topology for PB1, PB2, and HA genes appeared very similar, such that Yam-like and Vic-like viruses were clustered in Lineage II and III, respectively. On the other hand, the phylogenetic trees of PA, NP, NA and MP genes showed that all viruses were clustered in Lineage II (Yam-like). Furthermore, phylogenetic analysis of the NS gene showed that all viruses clustered together to form a distinct Lineage IV. The incongruent phylogenetic patterns observed at the lineage level corroborated with previous reports \[[@pone.0170610.ref007], [@pone.0170610.ref013], [@pone.0170610.ref015], [@pone.0170610.ref016]\], which suggest that the phylogenies of eight gene segments could be divided into three distinct evolutionary profiles: (i) PB1, PB2 and HA genes derived from either Lineage II or III; (ii) PA, NP, NA and MP genes derived from Lineage II; and (iii) NS genes derived from Lineage IV. Firstly, the consistent grouping of Yam-like or Vic-like viruses in Lineage II or III, respectively, in the tree topology of PB1, PB2 and HA genes could be attributed to possible genetic linkage between these three gene segments, which has been described \[[@pone.0170610.ref008]\]. They suggested that this pattern of co-assortment is due to the action of selection and would possibly have an effect on the whole-genome fitness of influenza B viruses \[[@pone.0170610.ref008]\], but the origin of this strong genetic linkage between these segments remains unclear. Secondly, for PA, NP, NA and MP gene segments, their highly similar evolutionary patterns also suggest possible functional association among the proteins \[[@pone.0170610.ref013]--[@pone.0170610.ref015]\], though such association remains to be investigated. Lastly, a separate lineage (Lineage IV) exhibited in the NS tree suggests that all Yam-like and Vic-like viruses possessed a NS gene segment with an unknown origin and reassortment event \[[@pone.0170610.ref007]\]. Taken together, the distinct evolutionary profiles shared between certain gene segments indicate that some of these genes would likely reassort together between lineages. However, whether the disappearance of a lineage in a gene segment (particularly the absence of Lineage III in PA, NP, NA and MP; Lineage II and III in NS) from the population is permanent or transient requires a large-scale analysis of genetic data.

![Phylogenetic comparsion based on nucleotdie sequences of PB1, PB2, PA, HA, NP, NA, MP and NS genes with that of WHO candidate vaccine (marked with \#) and reference strains, Malaysian influenza B/Phuket/3073/2013-like viruses and unique reassortants (marked in black circles), and strains from different countries (in italic).\
Phylogenetic trees were reconstructed by maximum likelihood (ML) method with 1,000 bootstrap replicates using PAUP 4.0. Bootstrap values ≥60 are shown. Scale bar represents a genetic distance of 0.01 substitutions/site.](pone.0170610.g001){#pone.0170610.g001}

The pattern of genetic reassortment became slightly less complex when influenza B viruses were phylogenetically classified into three major clades following the WHO genetic groupings \[[@pone.0170610.ref011], [@pone.0170610.ref012]\] for all gene segments: Victoria Clade 1 (Vic-1, represented by B/Brisbane/60/2008-like viruses), Yamagata Clade 1 (Yam-1, represented by B/Florida/4/2006-like viruses), Yamagata Clade 2 (Yam-2, represented by B/Brisbane/3/2007-like viruses) and Yamagata Clade 3 (Yam-3, represented by B/Bangladesh/3333/2007) ([Fig 1](#pone.0170610.g001){ref-type="fig"}). The tree topology showing three distinct clusters represented by major clades of Vic-1, Yam-2 and Yam-3 was similar in most of the gene segments except for the NP gene in which all Vic-1-like viruses appeared to reside within Yam-3. The sharing of a common ancestor between Vic-1-like viruses and B/Wisconsin/01/2010-like viruses (Yam-3-like viruses) in the NP gene was not observed for PA, NA and MP genes, even though previous observation at the lineage level showed that all four genes of Vic-like viruses were derived from Lineage II (Yam-like). This suggests that all Vic-1-like viruses selected in this study had an intra-lineage (or inter-clade) reassortment event that involved only the NP gene. To our knowledge, this unique reassortment property, observed in one of our Malaysian Vic-1-like virus (B/Malaysia/U1429/2012) as well as other B/Brisbane/60/2008-like viruses (Figs [1](#pone.0170610.g001){ref-type="fig"} and [2](#pone.0170610.g002){ref-type="fig"}) have not been described in any reports of the whole-genome analysis of influenza B viruses.

![Reassortment properties of the Malaysian B/Phuket/3073/2013-like viruses and unique reassortants at the lineage, clade and sub-clade level.](pone.0170610.g002){#pone.0170610.g002}

In addition, one of our unique inter-clade reassortants (B/Malaysia/U2214/2013) which possessed HA-Yam-2/NA-Yam-3 had a genomic pattern of HA and NP that derived from Yam-2 while the rest of the gene segments were derived from Yam-3 (Figs [1](#pone.0170610.g001){ref-type="fig"} and [2](#pone.0170610.g002){ref-type="fig"}). It was initially expected that PB1, PB2 and HA would derive from the same clade of Yam-2, given that a previous report suggested these three gene segments would tend to co-assort during a reassortment event \[[@pone.0170610.ref008]\]. As such unique reassortment pattern from B/Malaysia/U2214/2013 virus was not observed in the majority of other 'pure' Yam-3-like or Yam-2-like viruses ([Fig 1](#pone.0170610.g001){ref-type="fig"} and [S3 Fig](#pone.0170610.s003){ref-type="supplementary-material"}), this phenomenon could possibly be attributed to a random intra-lineage (or inter-clade) reassortment event within the Yamagata lineage \[[@pone.0170610.ref018], [@pone.0170610.ref027]\].

Reassortment of gene segments within the major circulating clades was further investigated. Using the HA phylogeny as a reference for phylogenetic classification of other gene segments, two monophyletic clusters observed within Yam-3 were first given a designation of Wisconsin/01-like and Stockholm/12-like sub-clades \[[@pone.0170610.ref010]\], representing B/Wisconsin/01/2010-like and B/Stockholm/12/2011-like viruses, respectively ([Fig 1](#pone.0170610.g001){ref-type="fig"}). For Vic-1, two monophyletic clusters were also observed within this clade, provisionally named as Victoria-1A sub-clade (Vic-1A: represented by B/Brisbane/60/2008-like or B/Texas/02/2013-like viruses) and Victoria-1B sub-clade (Vic-1B: represented by B/Hong Kong/514/2008-like or B/Hong Kong/259/2010-like viruses) ([Fig 1](#pone.0170610.g001){ref-type="fig"}). Phylogenetic classification and designation of these clusters have not been widely reported as most studies and WHO interim reports on influenza vaccines did not classify influenza B viruses beyond the three major circulating clades (Yam-2, Yam-3 and Vic-1) \[[@pone.0170610.ref011]--[@pone.0170610.ref013], [@pone.0170610.ref028], [@pone.0170610.ref029]\]. By adapting the only influenza virus clade definition criteria developed and reported by the WHO/OIE/FAO H5N1 Evolution Working Group (WHO/OIE/FAO, 2012), phylogenetic analyses and nucleotide sequence divergence calculations of all gene segments showed that these four clusters shared a common ancestral node, had a monophyletic grouping with a bootstrap value of ≥60 and maintained an average within- and between-clade pairwise nucleotide distance of ≤1.5% and ≥1.5%, respectively. However, in the MP and NS phylogenetic trees, a unique and previously unrecognized monophyletic cluster was observed, which was provisionally assigned as Victoria-1C sub-clade (Vic-1C). Viruses within this sub-clade shared a common ancestral node with a bootstrap value of ≥70, and had an average percentage of pairwise nucleotide distances between clades (comparing with Vic-1A and Vic-1B) of 1.16 ± 0.3% and 1.46 ± 0.3%, respectively, similar to the cutoff of 1.5% set in the criteria mentioned \[[@pone.0170610.ref030]\]. For Yam-2, only one cluster was observed for all gene segments, namely Massachusetts/02-like sub-clade (represented by B/Massachusetts/02/2012-like viruses) ([Fig 1](#pone.0170610.g001){ref-type="fig"}).

Based on phylogenetic analysis of only HA and NA genes, we initially deduced that the four Malaysian viruses were B/Phuket/3073/2013-like viruses within Yam-3, due to observation of intra-clade reassortment between HA and NA \[[@pone.0170610.ref010]\]. However, to our surprise, when all gene segments were phylogenetically analyzed and classified at the sub-clade level, it was observed that only three Malaysian B/Phuket/3073/2013-like viruses (B/Malaysia/U2555/2013, B/Malaysia/U3224/2013 and B/Malaysia/U3901/2014) and other B/Phuket/3073/2013-like candidate vaccine strains (B/Brisbane/09/2014 and B/Utah/08/2014) were classified as intra-clade reassortants within Yam-3 (Figs [1](#pone.0170610.g001){ref-type="fig"} and [2](#pone.0170610.g002){ref-type="fig"}). They possessed PB1, PB2, HA, NP, MP and NS genes that were grouped under the Wisconsin/01-like sub-clade while their PA and NA genes were grouped under the Stockholm/12-like sub-clade. As shown earlier, the evolutionary patterns of PA, NP, NA and MP genes of Vic-like and Yam-like viruses at the lineage level are similar in which they were grouped under Lineage II, suggesting possible co-assortment of these genes. However, evolutionary patterns at the sub-clade level further shows that PA and NA genes have a higher tendency to co-assort during reassortment of gene segments. Whether such co-assortment is due to a "functional linkage" between both gene segments in influenza B genome or due to a random reassortment event that increases the fitness of the virus and results in the global emergence of B/Phuket/3073/2013-like viruses remain to be elucidated.

While the other presumably B/Phuket/3073/2013-like virus (B/Malaysia/U2462/2012) had seven gene segments that were phylogenetically identical to B/Phuket/3073/2013-like viruses, the NS gene was derived from B/Stockholm/12/2011-like virus instead of B/Wisconsin/01/2010-like virus. Hence it was re-classified as a unique reassortant instead of a B/Phuket/3073/2013-like virus (Figs [1](#pone.0170610.g001){ref-type="fig"} and [2](#pone.0170610.g002){ref-type="fig"}). No other B/Phuket/3073/2013-like viruses were found to share similar reassortment pattern with B/Malaysia/U2462/2012 ([S3 Fig](#pone.0170610.s003){ref-type="supplementary-material"}). For the other unique reassortants found based on phylogenetic analysis of HA and NA genes, the inter-clade reassortant (B/Malaysia/U2214/2013 which had HA-Yam-2-like/NA-Yam-3-like) had a NS gene that derived from B/Wisconsin/01/2010-like virus instead of B/Stockholm/12/2011-like virus. In addition, the Vic-like inter-lineage reassortant (B/Malaysia/U1429/2012) also showed inter- and intra-clade reassortment properties (PB2 and HA derived from Vic-1B; PB1, PA, NP, and NA from Vic-1A; MP and NS from Vic-1C). This pattern was also observed in only one Asian virus, B/Thailand/CU-B6240/2012, which shared identical reassortment properties with B/Malaysia/U1429/2012 ([Fig 1](#pone.0170610.g001){ref-type="fig"} and [S3 Fig](#pone.0170610.s003){ref-type="supplementary-material"}). With that, the phylogeny of each gene segments observed at the sub-clade level in these unique reassortants suggests that a random reassortment event within a clade may occur and these reassortants are probably circulating at a very low level \[[@pone.0170610.ref018], [@pone.0170610.ref027]\]. Of note, the overall genetic makeup of these unique reassortants were distinct from the WHO recommended Yamagata-like (B/Wisconsin/01/2010-like in 2013, B/Massachusetts/02/2012 in 2014, B/Phuket/3073/2013 in 2015 and 2016) and Victoria-like (B/Brisbane/60/2008-like from 2012 to 2016 and B/Hong Kong/259/2010-like from 2014 to 2016) vaccine strains for the Southern Hemisphere ([Fig 2](#pone.0170610.g002){ref-type="fig"}). As information regarding the vaccine uptake of patients infected by these unique reassortants were not recorded, whether such reassortants caused more severe disease than the predominant circulating strains with enhanced viral fitness or whether they were able to be recognized effectively by antibodies generated by the recommended vaccine strains remains in question. Hence, influenza surveillance coupled with phylogenetic analyses should be intensified in order to detect more low-level circulating unique reassortants that may contribute to future outbreaks.

In conclusion, this present study highlights the strategy used for the phylogenetic classification of all gene segments of influenza B viruses, which classifies all genes at the lineage, clade and sub-clade level. This strategy for lineage classification was adapted from previously reported methods \[[@pone.0170610.ref007], [@pone.0170610.ref013], [@pone.0170610.ref015], [@pone.0170610.ref016]\], while the strategy for clade and sub-clade classification was adapted from the WHO interim reports \[[@pone.0170610.ref011], [@pone.0170610.ref012]\] and criteria used for H5N1 classification \[[@pone.0170610.ref030]\], respectively. Adaptation of this approach in future studies with a larger dataset of whole-genome sequences may perhaps allow a better understanding of the complexity of segment reassortments in influenza B evolution which may contribute to future vaccine design, and also for better monitoring of unique reassortants in surveillance studies.
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###### Phylogenetic anlaysis of the HA gene of influenza B viruses in Malaysia using the maximum likelihood (ML) method with 1,000 bootstrap replicates using PAUP 4.0 with complete taxa identity.
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Analyses began by retrieving complete genomes of 6,832 influenza B isolates from GISAID database. With this set of data, phylogenetic analysis on the HA gene was performed and a total of 51 strains were found to be closely related (by forming a cluster and have ≥99% sequence identities in BLAST) with our reassortants. These 51 strains were then used as references for all gene segments. Bootstrap values ≥60 are shown. Malaysian B/Phuket/3073/2013-like viruses and unique reassortants are highlighted in bold. Scale bar represents a genetic distance of 0.01 substitutions/site.
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